Phathom Pharmaceuticals Inc (PHAT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.54 (-2.71%), Market cap $0.95B, 52-week low–high $3.90 ~ $18.08.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey
Financial statements, price targets, institutional (13F) holdings and related news for Phathom Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Phathom Pharmaceuticals Inc trades at $7.54 (-2.71%). Real-time quotes and charts are available on BlackAll Trade.
Phathom Pharmaceuticals Inc has a market cap of about $0.95B.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has com